In contrast, prescription treatments such as oral semaglutide tablets, daily liraglutide injections, weekly semaglutide injections, and dual GLP-1/GIP therapies like tirzepatide are supported by large-scale clinical trials
In the scientific literature, the molecule is described as a single peptide with a multi-receptor profile of action, designed to simultaneously modulate several key metabolic axes
It balances the action of insulin, which is secreted from the pancreatic islet beta cells in response to hyperglycemia
Compensatory mechanisms activated with intermittent energy restriction: a randomized control trial
Despite this, Novo Nordisk remains committed to CagriSema as the potential first approved GLP-1 and amylin combination product
The trial included 2,339 adults with obesity or overweight plus at least one weight-related health problem, although people with diabetes were excluded